Overview

Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO

Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
0
Participant gender:
Male
Summary
comparing the outcome of low-intensity shock wave therapy (Li-SWT) versus solifenacin on persistent storage symptoms after transurethral surgery for benign prostatic obstruction (BPO)
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University
Treatments:
Solifenacin Succinate
Criteria
Inclusion Criteria:

- Patients have to fulfill all the following criteria to be included in the study:

1. Ability to give informed consent and reply to questionnaires.

2. Average urgency episodes per 24 hrs ≥ 1 and average daytime frequency ≥ 8 during
the baseline 3-day voiding diary.

3. Relief of BOO as proved by non-invasive uroflowmetry, pressure flow study (PFS)
or urethrocystoscopy.

Exclusion Criteria:

- Patients who have any of the following will be excluded from the study:

1. Untreated UTI.

2. BOO such as bladder neck contracture (BNC), residual obstructing adenoma or
urethral stricture.

3. Neurogenic lower urinary tract dysfunction (LUTD).

4. Uncontrolled diabetes mellitus.

5. Depression or any psychogenic disorders.

6. Prior radiation therapy to the pelvic area.

7. History of prostate cancer, bladder tumor or intravesical Bacillus Calmette
Guerin (BCG) therapy.

8. Poor coagulopathy.

9. Severe cardiovascular disease.